Source: Eur Respir Rev 2008; 17: 151-156
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Keane M. P.. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev 2008; 17: 151-156

Member's Comments

No comment yet.

Related content which might interest you: M2 polarized alveolar macrophages in pulmonary fibrosis Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of IL-11 in vascular function of pulmonary fibrosis patients Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004 Role of IL23 in the development of fibrotic interstitial lung disease Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 The RANKL-OPG balance in pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Role of Wnt-1, Wnt-3 and MMP-7 in fibrotic response in extrinsic allergic alveolitis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Interleukin-17 (IL-17) contributes to silica-induced alveolitis but is not essential in fibrosis development Source: Eur Respir J 2006; 28: Suppl. 50, 675s Year: 2006 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Disturbance of pro-inflammatory cytokine production in patients with cystic fibrosis lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 404s Year: 2005 The pathogenesis of pulmonary fibrosis: a moving target Source: Eur Respir J 2013; 41: 1207-1218 Year: 2013 Increased CCL18 production in interstitial lung diseases is associated with fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 38s Year: 2004 High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Apoptosis in lung injury and fibrosis Source: Eur Respir J 2008; 32: 1631-1638 Year: 2008 Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases Source: Eur Respir J 2008; 32: 1068-1081 Year: 2008